Pharmacogenetics - Significance in chemotherapy of colorectal cancer;Farmakogenetyka - Znaczenie w chemioterapii raka jelita grubego

Nowotwory

Volumn 58, Issue 1, 2008, Pages 62-69

  Panczyk, Mariusz ^a   Mirowski, Marek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Colorectal cancer; Individualization of therapy; Pharmacogenetics

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CYCLIN D1; FLUOROURACIL; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; OXALIPLATIN;

CANCER CHEMOTHERAPY; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT;

EID: 41949125554     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. de Gramont A, Figer A, Seymour M i wsp. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-47.
2. Saltz LB, Cox JV, Blanke C i wsp. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.
3. Danenberg PV. Thymidylate synthetase - a target enzyme in cancer chemotherapy.Biochim Biophys Acta 1977 473: 73-92.
4. Watanabe T, Wu TT, Catalano PJ i wsp. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-206.
5. Horie N, Aiba H, Oguro K i wsp. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-7.
6. Mandola MV, Stoehlmacher J, Muller-Weeks S i wsp. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898-904.
7. Heggie GD, Sommadossi JP, Cross DS i wsp. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987;47: 2203-6.
8. McLeod HL, Collie-Duguid ES, Vreken P i wsp. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8: 455-9.
9. van Kuilenburg AB, Vreken P, Abeling NG i wsp. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1-9.
10. van Kuilenburg AB, Muller EW, Haasjes J i wsp. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 2001; 7: 1149-53.
11. van Kuilenburg AB, Haasjes J, Richel DJ i wsp. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-12.
12. Isshi K, Sakuyama T, Gen T i wsp. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 2002; 7: 335-42.
13. Ichikawa W, Takahashi T, Suto K i wsp. Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen. Clin Cancer Res 2006; 12: 3928-34.
14. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000; 61: 199-203.
15. Cohen V, Panet-Raymond V, Sabbaghian N i wsp. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003; 9: 1611-5.
16. Vanhoefer U, Harstrick A, Achterrath W i wsp. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol. 2001; 19: 1501-18.
17. Humerickhouse R, Lohrbach K, Li L i wsp. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60: 1189-92.
18. Charasson V, Bellott R, Meynard D i wsp. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 2004; 76: 528-35.
19. Iyer L, King CD, Whitington PF i wsp. Genetic predisposition to the metabolism of irinotecan (CPT-H). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-54.
20. Ando Y, Saka H, Ando M i wsp. Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6.
21. Kitagawa C, Ando M, Ando Y i wsp. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet Genomics 2005; 15: 35-41.
22. Koiwai O, Yasui Y, Hasada K i wsp. Three Japanese patients with Crigler-Najjar syndrome type I carry an identical nonsense mutation in the gene for UDP-glucuronosyltransferase. Jpn J Hum Genet 1995; 40: 253-7.
23. Gagne JF, Montminy V, Belanger P i wsp. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10- hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62: 608-17.
24. Jinno H, Saeki M, Saito Y i wsp. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther 2003; 306: 688-93.
25. Boudny V, Vrana O, Gaucheron F i wsp. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 1992; 20: 267-72.
26. Shirota Y, Stoehlmacher J, Brabender J i wsp. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-304.
27. Sweeney C, McClure GY, Fares MY i wsp. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000; 60: 5621-4.
28. Allen WL, Johnston PG. Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. Pharmacogenomics 2005; 6: 603-14.
29. Wilson MD, Ruttan CC, Koop BF i wsp. ERCC1: a comparative genomic perspective. Environ Mol Mutagen 2001; 38: 209-15.
30. Park DJ, Zhang W, Stoehlmacher J i wsp. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 2003; 1: 162-6.
31. Sung P, Bailly V, Weber C i wsp. Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature 1993; 365: 852-5.
32. Spitz MR, Wu X, Wang Y i wsp. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61: 1354-7.
33. Park DJ, Stoehlmacher J, Zhang W i wsp. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 2001; 61: 8654-8.
34. Boyer TD, Vessey DA, Holcomb C i wsp. Studies of the relationship between the catalytic activity and binding of non-substrate ligands by the glutathione S-transferases. Biochem J 1984; 217: 179-85.
35. Tsuchida S, Sato K. Glutathione transferases and cancer. Crit Rev Biochem Mol Biol 1992; 27: 337-84.
36. Srivastava SK, Singhal SS, Hu X i wsp. Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 1999; 366: 89-94.
37. Stoehlmacher J, Park DJ, Zhang W i wsp. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002; 94: 936-42.
38. Nygren P, Sorbye H, Osterlund P i wsp. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol 2005; 44: 203-17.
39. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 2958-70.
40. Utracka-Hutka B. Targeted therapy of colorectal cancer - state of the art. Współczesna Onkologia 2006; 10: 121-7.
41. Tabernero J, Macarulla T, Ramos FJ i wsp. Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 2005; 16: 1740-8.
42. Gebhardt F, Zanker KS, Brandt B. Modulation of epidermal growth factor receptor gene transcription by a polymorphic dinucleotide repeat in intron 1. J Biol Chem 1999; 274: 13176-80.
43. McKay JA, Murray LJ, Curran S i wsp. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002; 38: 2258-64.
44. Zhang W, Park DJ, Lu B i wsp. Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 2005; 11: 600-5.
45. Chung KY, Shia J, Kemeny NE i wsp. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-10.
46. Zhang W, Gordon M, Press OA i wsp. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 2006; 16: 475-83.
47. Kern SE, Fearon ER, Tersmette KW i wsp. Clinical and pathological associations with allelic loss in colorectal carcinoma [corrected]. JAMA 1989; 261: 3099-103.
48. Tang R, Wang JY, Fan CW i wsp. p53 is an independent pre-treatment markers for long-term survival in stage II and III colorectal cancers: an analysis of interaction between genetic markers and fluorouracil-based adjuvant therapy. Cancer Lett 2004; 210: 101-9.
49. Ahnen DJ, Feigl P, Quan G i wsp. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res 1998; 58: 1149-58.
50. Watanabe T, Wu TT, Catalano PJ i wsp. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-206.
51. Papadimitrakopoulou VA, Oh Y, El-Naggar A i wsp. Presence of multiple incontiguous deleted regions at the long arm of chromosome 18 in head and neck cancer. Clin Cancer Res 1998; 4: 539-44.
52. Gryfe R, Kim H, Hsieh ET i wsp. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69-77.
53. Lim SB, Jeong SY, Lee MR i wsp. Prognostic significance of microsatellite instability in sporadic colorectal cancer. Int J Colorectal Dis 2004; 19: 533-7.
54. Ribic CM, Sargent DJ, Moore MJ i wsp. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-57.
55. Lu SL, Zhang WC, Akiyama Y i wsp. Genomic structure of the transforming growth factor beta type II receptor gene and its mutations in hereditary nonpolyposis colorectal cancers. Cancer Res 1996; 56: 4595-8.
56. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.